Hector Lopez de la Garza

Hector Lopez de la Garza

Auto-generated profile, based on publicly available information

Hector Lopez de la Garza

Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Nuevo Leon, Mexico

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2021 in Thrombosis Journal
Verified
Journal Article
Open access
PDF file
MCMauricio Castillo-Perez
Mauricio Castillo-Perez
CJCarlos Jerjes-Sanchez
Carlos Jerjes-Sanchez
ACAlejandra Castro-Varela
Alejandra Castro-Varela
JPJose Gildardo Paredes-Vazquez
Jose Gildardo Paredes-Vazquez
EVEduardo Vázquez-Garza
Eduardo Vázquez-Garza
JPJathniel Panneflek
Jathniel Panneflek
To our knowledge, the treatment, outcome, clinical presentation, risk stratification of patients with venous thromboembolism and COVID-19 have not been well characterized. We searched for systematic reviews, cohorts, case series, case reports, editor letters, and venous thromboembolism COVID-19 patients’ abstracts following PRISMA and PROSPERO statements. We analyzed therapeutic approaches and clinical outcomes of venous thromboembolism COVID-19 patients. Inclusion: COVID-19 patients with venous thromboembolism confirmed by an imaging method (venous doppler ultrasound, ventilation-perfusion lung scan, computed tomography pulmonary angiogram, pulmonary angiography). We assessed and reported the original Pulmonary Embolism Severity Index for each pulmonary embolism patient. In addition, we defined major bleedings according to the International Society of Thrombosis and Haemostasis criteria. We performed a systematic review from August 9 to August 30, 2020. We collected 1,535 papers from PubMed, Scopus, Web of Science, Wiley, and Opengrey. We extracted data from 89 studies that describe 143 patients. Unfractionated and low-molecular-weight heparin was used as parenteral anticoagulation in 85/143 (59%) cases. The Food and Drug Administration-approved alteplase regimen guided the advanced treatment in 39/143 (27%) patients. The mortality was high (21.6%, CI 95% 15.2-29.3). The incidence of major bleeding complications was 1 (0.9%) in the survival group and 1 (3.2%) in the death group. Pulmonary Embolism Severity Index was class I in 11.6% and II in 22.3% in survivors compared to 0% and 6.5% in non-survivors, respectively. Patients who experienced venous thromboembolism events at home were more likely to live than in-hospital events. We determined a high mortality incidence of pulmonary embolism and a low rate of bleeding. Unfractionated and low-molecular-weight heparin drove parenteral anticoagulation and alteplase the advanced treatment in both groups. The original Pulmonary Embolism Severity Index could be helpful in the risk stratification.

1 December 2020 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
HCHector Betancourt-Del Campo
Hector Betancourt-Del Campo
CJCarlos Jerjes-Sanchez
Carlos Jerjes-Sanchez
MCMauricio Castillo-Perez
Mauricio Castillo-Perez
HGHector López-De la Garza
Hector López-De la Garza
JPJose Gildardo Paredes-Vazquez
Jose Gildardo Paredes-Vazquez
MIMarcos Ibarra-Flores
Marcos Ibarra-Flores
Background: From asymptomatic patients to severe acute respiratory distress syndrome, COVID-19 has a wide range of clinical presentations, and venous thromboembolism has emerged as a critical and frequent complication. Case summary: We present a case of a 69-year-old man with a clinical presentation of massive-like pulmonary embolism (PE) overlapping with severe COVID-19 pneumonia. The diagnosis was made based on hypotension, severe oxygen desaturation (33%), and right ventricular dysfunction (RVD). We used alteplase and low-molecular-weight heparin, obtaining immediate clinical improvement. Also, we identified an extremely elevated D-dimer (31.2 mcg/mL), and computed tomography pulmonary angiography (CTPA) revealed an unexpected low thrombus burden and a crazy-paving pattern. Considering this, we decided to discontinue the alteplase. Therefore, the mechanisms of pulmonary hypertension and RVD could be multifactorial. Despite the patient’s respiratory status worsening and ongoing mechanical ventilation, biomarkers kept lowering to normal ranges. It appears a favourable outcome was related to early PE diagnosis and a multimodal therapeutic approach. Discussion: Physicians in the ER should be warned about extremely high D-dimer measurements and severe oxygen desaturation as possible markers of severe COVID-19 pneumonia in patients with high-clinical suspicion of PE. Although ESC guidelines recommend immediate reperfusion in cardiogenic shock secondary to PE, we suggest initial CTPA in patients with high-clinical suspicion of severe COVID-19.

10 January 2017 in Journal of Advances in Medicine and Medical Research
Verified
Journal Article
Closed access
EPEmma Purón-González
Emma Purón-González
FGFernando Garza-Salazar
Fernando Garza-Salazar
RMRogelio Maya-Quinta
Rogelio Maya-Quinta
ECEdgar Coronado-Alejandro
Edgar Coronado-Alejandro
HGHéctor Garza
Héctor Garza

10 January 2017 in British Journal of Medicine and Medical Research
Verified
Journal Article
Open access
PDF file
FGFernando Garza-Salazar
Fernando Garza-Salazar
FGFernando Góngora-Rivera
Fernando Góngora-Rivera
HGHector Garza
Hector Garza
EPEmma Purón-González
Emma Purón-González
JHJorge Alberto Hernandez-Portales
Jorge Alberto Hernandez-Portales
Aims: Dengue virus is a mosquito-born viral disease that infects about 390 million people each year. The clinical manifestations are fever, arthralgia and myalgia. Guillain-Barré Syndrome (GBS) caused by dengue fever has been rarely reported. Presentation of Case: A 46-year-old man with no relevant medical history was seen because of progressive quadriparesis, dysautonomia, dysphagia and facial paresia. Ten days before seeking medical care the patient had fever, myalgia, arthralgia, rash, thrombocytopenia, and a positive NS1 dengue antigen. GBS was suspected and immunoglobulin was started while nerve conduction studies confirmed an acute motor axonal polyradiculoneuropathy. According to Brighton criteria, the patient was classified with a level 2 diagnostic certainty, since it was decided to not perform lumbar puncture for CSF analysis. The patient had a good clinical response and was subsequently discharged. Discussion: Dengue virus is arthropod-borne. It presents with high fever, rash, arthralgia, myalgia, and in rare cases, neurological complications such as GBS. In Mexico, there were 14,112 confirmed cases of non-severe dengue and 3,683 cases of severe dengue or with warning signs in 2016. There are no reported cases of GBS secondary to dengue infection in this country. Conclusion: GBS following dengue fever should be considered in countries with a high incidence of dengue infection such as Mexico even if there are no previous manifestations of dengue fever.

10 February 2026 in Therapeutic Advances in Cardiovascular Disease
Verified
Journal Article
Open access
HGHector Lopez-De la Garza
Hector Lopez-De la Garza
CJCarlos Jerjes-Sanchez
Carlos Jerjes-Sanchez
VLVictor E. Lozano-Corres
Victor E. Lozano-Corres
CMChristian Camacho Mondragon
Christian Camacho Mondragon
MRMaria Fernanda Reyes-Chavez
Maria Fernanda Reyes-Chavez
CJCecilia Gocher Janet
Cecilia Gocher Janet
Background: Despite continuous advances in management over the last two decades for pulmonary embolism (PE), treating intermediate- to high-risk PE remains challenging. There is a critical need to expand our understanding of the clinical spectrum beyond systolic blood pressure (SBP) to inform the intricate decision-making process for initiating advanced treatment in patients with intermediate- to high-risk PE. Objectives: We aimed to characterize the range of SBP values in patients with intermediate- to high-risk PE undergoing advanced therapy across different clinical settings. The secondary objective included the incidence of bleeding complications (intracranial, major, and minor). Design: We conducted a systematic review in alignment with PRISMA guidelines. The review involves a comprehensive, structured search of multiple electronic databases. Data sources and methods: We created two groups: Group 1, case reports and series, and Group 2, randomized control trials and cohorts with intermediate-risk PE who underwent advanced treatment. In addition, we performed an exploratory analysis in Group 1, created solely for descriptive purposes, to determine the frequency of the previously mentioned impending deterioration factors in the literature and further clarify their potential role in initiating advanced treatment. Results: We identified 1871 intermediate-high risk PE patients who received advanced therapy, divided into two groups: Group 1 for case reports and series, and Group 2 for randomized controlled trials and cohorts. In total, 77.1% reported SBP; the weighted average was 125.8 and 129.2 mmHg for Groups 1 and 2, respectively. The most common initial clinical presentations were dyspnea, syncope, and chest pain. In the exploratory analysis, we found that borderline SBP (110–120 mmHg), right ventricular dysfunction, and heart rate (⩾120 bpm) were the most frequent impending clinical deterioration factors. Conclusion: This systematic review shows that the SBP range for advanced treatment (129.2 and 125.8 mmHg) aligns with previous clinical models. However, it is important to recognize that while these SBP ranges may suggest practice variation, causality or definitive clinical instability cannot be inferred from aggregate data without patient-level outcomes. Outside of randomized controlled trials, clinical decision-making regarding advanced treatment may not fully align with international recommendations in real-world scenarios. Trial registration: Research Registry number: 2065.

1 March 2020 in JACC
Verified
Journal Article
Closed access
VFVicente Jimenez Franco
Vicente Jimenez Franco
RHRosana Hernandez-Antolin
Rosana Hernandez-Antolin
HGHector Lopez de la Garza
Hector Lopez de la Garza
JPJosé Gildardo Paredes-Vázquez
José Gildardo Paredes-Vázquez